Intech Investment Management LLC Buys New Position in RxSight, Inc. (NASDAQ:RXST)

Intech Investment Management LLC acquired a new stake in RxSight, Inc. (NASDAQ:RXST - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 12,091 shares of the company's stock, valued at approximately $598,000.

Other large investors have also added to or reduced their stakes in the company. Quest Partners LLC increased its position in RxSight by 346.1% in the 3rd quarter. Quest Partners LLC now owns 3,069 shares of the company's stock valued at $152,000 after acquiring an additional 2,381 shares during the period. Thrivent Financial for Lutherans bought a new stake in shares of RxSight in the third quarter worth $11,350,000. RiverPark Advisors LLC increased its holdings in RxSight by 42.1% in the third quarter. RiverPark Advisors LLC now owns 4,800 shares of the company's stock valued at $237,000 after purchasing an additional 1,421 shares during the period. Paragon Advisors LLC raised its position in RxSight by 3.1% during the 3rd quarter. Paragon Advisors LLC now owns 31,399 shares of the company's stock worth $1,552,000 after purchasing an additional 935 shares during the last quarter. Finally, KBC Group NV lifted its holdings in RxSight by 63.6% during the 3rd quarter. KBC Group NV now owns 1,232 shares of the company's stock worth $61,000 after buying an additional 479 shares during the period. Institutional investors own 78.78% of the company's stock.

RxSight Price Performance

Shares of RxSight stock traded up $0.48 during trading on Friday, reaching $46.88. 254,146 shares of the company traded hands, compared to its average volume of 683,749. The firm has a market capitalization of $1.89 billion, a PE ratio of -56.48 and a beta of 1.19. RxSight, Inc. has a 1-year low of $28.88 and a 1-year high of $66.54. The company has a 50 day moving average price of $48.58 and a 200-day moving average price of $52.26.

Insider Transactions at RxSight

In other news, insider Ilya Goldshleger sold 3,100 shares of the company's stock in a transaction that occurred on Monday, September 23rd. The stock was sold at an average price of $52.67, for a total transaction of $163,277.00. Following the transaction, the insider now directly owns 42,246 shares of the company's stock, valued at $2,225,096.82. This represents a 6.84 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Shweta Maniar sold 3,782 shares of the stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $45.88, for a total value of $173,518.16. Following the completion of the transaction, the director now owns 10,902 shares in the company, valued at approximately $500,183.76. This represents a 25.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 62,702 shares of company stock valued at $3,059,197 in the last 90 days. 9.36% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on RXST. Oppenheimer decreased their price target on RxSight from $72.00 to $65.00 and set an "outperform" rating for the company in a research note on Tuesday, August 6th. Jefferies Financial Group started coverage on shares of RxSight in a report on Tuesday, October 29th. They set a "buy" rating and a $72.00 price target for the company. Wells Fargo & Company reduced their price objective on shares of RxSight from $68.00 to $54.00 and set an "overweight" rating on the stock in a research note on Tuesday, August 6th. Needham & Company LLC reiterated a "buy" rating and set a $66.00 price objective on shares of RxSight in a research report on Friday, September 13th. Finally, Stifel Nicolaus dropped their target price on shares of RxSight from $70.00 to $65.00 and set a "buy" rating on the stock in a report on Tuesday, August 6th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $61.63.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.